1 Min Read
June 1 (Reuters) - Arch Biopartners Inc :
* European Commission designated AB569 as orphan medicinal product in European Union for treatment of patients with cystic fibrosis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.